India: Patent Oppositions - An International Perspective

Last Updated: 20 November 2015
Article by Suchi Rai Singh and Akshay Mehta

Most Read Contributor in India, September 2016

A patent is an exclusive right granted to the inventor for a novel product or a novel process that provides, a unique way of doing something, or which discloses a new technical solution to a problem.2 Patents are provided as economic incentives for research and development and to facilitate and encourage disclosure of innovations so as to make it available in public domain. Laws providing for opposition of patent are essential to prevent wrongful grant of patent. However, this has led to undue delay in grant of patent, which has hit the main rationale behind incentive based patent system.

Opposition proceedings are structured to restrain wrongful obtaining of patents and claiming of the frivolous inventions. On 1st January 2005, India ratified the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement, due to which Section 25 of the Patents Act, 1970 ("The Act") was amended in light of the TRIPS agreement to introduce an integrated system of both pre-grant and post-grant opposition in India. Under Indian Patent act, there are two provisions when opposition may be filed either via pre-grant opposition or post-grant opposition provision depending upon the stage of the patent.


Section 25(1) of the Patent (Amendment) Act 2005 provides provisions for Pre-Grant opposition of Patent. Under this provision any person or any third party or Government may challenge the application of grant of patent and inform to the controller of Patents for opposition, before the grant of a patent, under Form 7(A) read with Rule 55 of the Patent Rules 2003..

Pre-grant opposition can be made on the grounds listed under section 25(1)(a) to (k) of the Patent (Amendment) Act, 2005. Pre-grant opposition acts as a defensive shield to confirm the validity of the patent applications before patents are granted to applicants. The efficacy of this provision has been widely debated because some argue that the pre-grant system can remedy the lack of information during the initial examination by the Patent Office and this contention has been opposed on the grounds that it delays the prosecution and consequent grant of patent.

This system of opposition has hit the pharmaceutical industry badly. Interestingly, in the Gleevec Case,3 the Constitutional validity of Section 3(d) was challenged in the Madras High Court at a time when there was no such similar section in any member country4. The refusal to grant patent by the Intellectual Property Appellate Board and the hon'ble Supreme Court of India, was seen as not a very good outcome in the International community and it was felt that it will be difficult for the foreign companies to work in India in such patent regime.


It acts like a second window under the Patent (Amendment) Act, 2005 which may be filed at any time after the grant of patent but before the expiry of a period of one year from the date of publication of grant of the patent. In accordance with Rule 55A of the Patent Rules, 2003 any person interested5 may give notice of opposition to the Controller, under Form 7 on any of the grounds mentioned in Section 25(2) of the Patent (Amendment) Act 2005. It is notable that many of the grounds are similar to the grounds required for filing pre-grant opposition and there is nothing to preclude a pre-grant opponent from subsequently filing a postgrant opposition.

The main drawback of the post-grant opposition process is that this remedy is available only through the courts, making redressal a lengthy process, and in the case of frivolous patents, allowing a patent holder to enjoy a wrongful monopoly.

In the case of Novartis AG v. UOI & Anr.,6 it is submitted that Novartis used the same base called imatinib and added it with a new acid known as mesylate which resulted into a new compound called imatinib mesylate. However, it was contended by Novartis that imatinib is in its new betacrystalline form instead of its earlier known alpha form. The opposition which came was that imatinib was earlier disclosed and mere change from its alpha form to betacrystalline form does not amount to a therapeutic change under Section 3(d) of The Act. Hence, the patent was not granted to Novartis inspite of the fact it was given a patent in other jurisdictions till 2005.


Pre-grant proceedings may be initiated by 'any person', while only a 'person interested' can introduce a post grant opposition. In addition to this, there can be no infringement proceedings during a pre-grant opposition as the patent does not cross the application stage. Patent opposition process has principally affected the pharmaceuticals industry because the patent applicants are now exposed to multiple pre-grant oppositions which have fuelled fears among innovator companies.


Opposition to any European patent granted by the EPO under the European Patent Convention, may be filed by any member of the public except for the proprietor himself. Opposition must be filed within nine months of the publication of the mention that the patent has been granted. The procedure may involve multiple opponents. In accordance with Article 100 EPC, any opposition may be filed. Notice of opposition may be filed online or in writing with the EPO (Munich, Hague or Berlin), and an opposition fee is payable as prescribed.


It relies predominantly upon the process of reexamination for arguing against the validity of a patent. Reexamination is conducted by the USPTO, with a course of appeal lying with the Court of Appeals for the Federal Circuit. Reexamination is only applicable to issued patents and it is ex parte in nature. A request for reexamination can be made under Section 3027 on the basis on any prior art cited under Section 3018. Moreover, it allows request for inter partes reexamination under Section 3119, under which any third party requester may file an application on the basis of the prior art cited. If a substantial new question of patentability is identified, then reexamination will be granted.

The US does not recognize any pre-grant opposition but allows for a protest under Chapter 190110 which is designed to bring information to the attention of the USPTO that is relevant to avoiding the issue of invalid patents. It occurs during patent prosecution and must be submitted prior to either the publication of the patent application, or the mailing of a notice of allowance, whichever occurs first.


A patent opposition process allows a person to challenge the validity of an innovation patent, or an application for a standard patent before it is granted. Patent oppositions can be made against an accepted standard patent application or a certified innovation patent. 11There have been changes in the opposition and following are the period for opposition:

For oppositions commenced on or after 15 April 2013: 12

Type of opposition

Time for filing a notice of opposition

Opposition to the grant of a patent (sec 59)

3 months from the publication of the acceptance of the application

Opposition to an innovation patent (sec 101M)

Any time after Certification

Opposition to an extension of term (sec 75)

3 months from the publication of the acceptance of the extension

Opposition to an amendment (sec 104)

2 months from the publication of the Grant of Leave to Amend *

Opposition to an extension of time (sec 223)

2 months from the publication of the extension

Opposition to the grant of a licence (reg 22.21)

2 months from being given a copy of the request for a licence

In the case of an opposition under section 104, the opposition period will remain 3 months if the amendment was advertised before 15 April 2013, and the notice of opposition is filed on or after 15 April 2013.


The Japanese patent system resembles the European patent system. Recent changes to Japanese patent law in 1996 included the move from a pre-Grant patent opposition system (three months to file opposition) to a post-Grant opposition system (six months to file opposition, but the patent is valid until declared otherwise). Under the old system, examined patents were published pre-grant ('kokoku'). The Patent Opposition System allows any party desiring to do so the opportunity to file an opposition to a granted patent after the patent right is granted. The goal of the Patent Opposition System is to increase public confidence in the patent system. When an opposition is filed, the Patent Office reexamines the appropriateness of its initial decision to grant the patent and remedies any flaws that are discovered. 13

In Japan, once a patent has been granted, it is published for opposition in the Patent Gazette. Any third party may file an opposition to the grant of a patent within six months of publication for opposition. The grounds for an opposition are similar to the grounds for rejection of an application by an examiner. In an opposition, however, grounds based on joint ownership, unity of the invention, claims not conforming to patent rules, and lack of right to obtain a patent are not applicable. As with an appeal, an opposition is most commonly heard by a group of three examiners. The patent owner will be given an opportunity to amend the specification or claims to the extent permitted after a final Office Action. 14

An unusual feature of the Japanese patent system is that applications are not automatically examined. The applicant has seven years from the filing date to file a request for examination. The patent is then usually examined in 24 to 30 months. However, as many applicants use this system to evaluate market developments, typical pendency between filing and examination is five to seven years. Some patent applications can be processed much faster, being examined and published within 15 to 18 months of filing.

Japan's Patent Law was amended in 2003 under which the post-grant opposition system was abolished, while the invalidation trial system was revised, w.e.f. 1st January 2004, to allow any entity to demand an invalidation trial without interest. 15 Under the new invalidation trial, the trial may be demanded at anytime, both parties are involved in adversary system during the trial procedure and the demanding party may appeal against the trial decision affirming the patent at issue to the Tokyo High Court.


When a patent has been granted in Switzerland, the title is entered into the Swiss Patent Register and published. Any person can file opposition against a patent with the Institute within nine months of the granting. The CHF 800 fee must be paid and the ground for the opposition must be in writing. The only acceptable ground for opposition is that the patent contains inventions which are excluded from patenting (Art. 1a, 1b and 2 Patent Act). Such inventions are, for example, the human body at all phases of formation and development, or naturally occurring sequences or partial sequences of genes.

Opposition can also be filed against inventions which are contrary to human dignity or disregard the dignity of a creature, or in any other way contrary to public convention or morality. If the novelty, inventive step or disclosure of the invention is missing, a petition for nullity must be filed, not opposition proceedings. The Institute decides whether the opposition should be rejected or the patent revoked, or whether the patent can be upheld with a modified scope. 16


1 Legal Intern

2 Section 2(1)(m) of The Patents Act, 1970

3 Novartis A.G. v. UOI & Anr. (2007)

4 MLJ 1153, Civil Appeal Nos. 2706-2716 of 2013. 4 TRIMS Agreement: Agreement on Trade-Related Investment Measures, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1A, THE LEGAL TEXTS: THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS 143 (1999), 1868 U.N.T.S. 186

5 Section 2(1)(t) of The Patents Act, 1970: includes a person engaged in, or in promoting, research in the same filed as that to which the invention relates. In addition, interested person may also include any organization that has a manufacturing or trading/ financial interest in the goods related to the patented product.

6 Civil Appeal Nos. 2706-2716 of 2013.

7 35 U.S.C. 302

8 35 U.S.C. 301

9 35 U.S.C. 311

10 37 CFR 1.291







The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.